HELX Fact Sheet: Franklin Genomic Advancements ETF
Share
$39.77
close, Nov 20, 2026
Over the year to Nov 19, 2026, HELX returned +14.9% in total and charged 0.50% a year.
- 1-year total return
- +12.2%
- to Nov 20, 2026
- Expense ratio
- 0.50%
- a year
- Net assets
- $33m
- on Nov 19, 2026
- Net flow, 12 months to Jun 30, 2026
- +$9.8m
- monthly N-PORT basis to Jun 30, 2026
Growth of $10,000, 1 year
HELX $11,494 +14.9% · IWV $10,940 +9.4% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.
Returns
WindowTotal return
1 month−8.4%
3 months−7.8%
Year to date+9.5%
1 year+12.2%
3 years+44.8%
5 years−21.1%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
GUARDANT HEALTH INC9.09%
NATERA INC7.46%
KRYSTAL BIOTECH INC6.33%
LIGAND PHARMACEUTICALS INC4.62%
ADAPTIVE BIOTECHNOLOGIES CORP3.99%
UNITED THERAPEUTICS CORP3.51%
BRIDGEBIO PHARMA INC3.50%
ELI LILLY & COMPANY2.95%
TWIST BIOSCIENCE CORP2.85%
VERTEX PHARMACEUTICALS INC2.75%
HELX top ten by weight, 47.0% of the fund, of its 61 equity positions, from the holdings filed for Jun 30, 2026.
Facts
Holds 61 stocks in healthcare innovation and GLP-1, 15% of its weight in S&P 500 companies · First traded Feb 27, 2020 · Benchmark Its own holdings, as of Jun 30, 2026